Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Expands By 123.2%

Biomerica, Inc. (NASDAQ:BMRA) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 92,289 shares, a growth of 123.2% from the December 15th total of 41,348 shares. Based on an average daily volume of 234,834 shares, the days-to-cover ratio is currently 0.4 days. Currently, 3.8% of the shares of the company are short sold. Currently, 3.8% of the shares of the company are short sold. Based on an average daily volume of 234,834 shares, the days-to-cover ratio is currently 0.4 days.

Biomerica Trading Up 1.1%

Shares of NASDAQ BMRA opened at $2.71 on Wednesday. The firm has a 50 day moving average of $2.47 and a 200 day moving average of $2.87. The firm has a market capitalization of $7.99 million, a price-to-earnings ratio of -2.82 and a beta of 0.11. Biomerica has a 12-month low of $2.11 and a 12-month high of $10.16.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biomerica in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.